Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Inclusion Criteria: * Having the ability to voluntarily give their signed informed consent. * Clinically healthy subjects. * Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures. * Age ≥ 18 years. * No history of contact lens wear * Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \[Tubal Ligation\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the ied consent form \[ICF\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period. * Having vital signs within normal parameters. * Best corrected visual acuity (BCVA) of 20/30 or better in both eyes. * Having an intraocular pressure ≥ 10 and ≤ 21 mmHg. Exclusion Criteria: * History of hypersensitivity to any of the components of the drugs under investigation. * Use of ophthalmic medications from any pharmacological group. * Use of medications by any other route of administration. * In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period. * Having participated in any clinical research study 30 days prior to inclusion in this study. * Having previously participated in this same study. * History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension. * Diagnosis of glaucoma or ocular hypertension. * Known diagnosis of liver or heart disease. * Presenti…